Tags: allogeneic haematopoietic stem-cell transplantation (HSCT)allogeneic hematopoietic cell transplantationblast-phase chronic myeloid leukaemiablast-phase chronic myeloid leukemiabloodcancerchemochemotherapychronic myeloid leukaemiachronic myeloid leukemiaCMLcytarabinedose limiting toxicityfilgrastimflag-idafludarabinegranulocyte colony-stimulating factor (G-CSF)grastofilhaematologyhematologyhemehigh risk populationHSCTidarubicinlapelgaleukaemialeukemiaonconcologypegfilgrastimphase 1 trialphase 2 trialponatinibstem cell transplantsurvivaltolerabilitytoxicitytransplanttyrosine kinase inhibitor
Want more physician-written
medical news?
Join over 10 million yearly readers and numerous companies. For healthcare professionals
and the public.
Subscribe for free today!